CEFT Panel Peptide
Quick Overview for CEFT Panel Peptide (ABIN6699450)
Target
Source
-
-
Peptide Type
- Synthetic
-
Supplier Product No.
- 000-001-l24
-
Supplier
- Rockland
-
Purpose
- T-Cell Assay Panel Peptides
-
Purification
- Greater than 90% specific peptide.
-
Purity
- Greater than 90% specific peptide.
-
-
-
-
Application Notes
-
Application Note: T-Cell Assay Panel Control Peptides are suitable for use in ELISA, Western Blot, Dot blot, PCA, and other assays. Control peptide should be used at 1.0 μg per 1.0 μL of antiserum in per assay. Specific conditions for reactivity should be optimized by the end user.
Other: Control peptide should be used at 1.0 μg per 1.0 μL of antiserum per assay.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
-
Reconstitution_Buffer: Restore with deionized water (or equivalent)
Reconstitution_Volume: 1.0 mL
-
Concentration
- 1.0 mg/mL
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store vial at 2 - 8 ° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. Dilute only prior to immediate use.
-
Expiry Date
- 12 months
-
-
- CEFT Panel
-
Background
-
Synonyms: Influenza A, Influenza M, EBV LMP2A, EBV BMLF1, HCMV pp65, Influenza NP, EBV, EBV EBNA 4NP, EBV RTA, EBV BZLF-1, EBV EBNA 3A, EBV EBNA 3, HCMV, EBV EBNA 3C, EBV EBNA3A, CMV pp65, HCMV, control peptide, blocking peptide
Background: Pool of 32 HLA class I restricted T cell epitopes from human cytomegalovirus, Epstein-Barr virus and influenza virus. Stimulates the release of IFN-gamma from CD8+ T cells in individuals with certain highly frequent HLA types (HLA: A1, A2, A3, A11, A24, A68, B7, B8, B27, B35, B44). Chosen epitopes are presented by the most common Caucasian HLA types, whose cumulative frequencies represent >100 % of Caucasian individuals. Useful as a peptide specific positive control in ELISPOT, CTL and intracellular cytokine assays using human PBMC.
Target
-
